| abstract |
Methods for the detection and screening of hepatocellular carcinoma (HCC) patients and for the monitoring of HCC treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. In other aspects, methods for detection and screening for the progression of high-risk conditions, such as HCV infections, to HCC and to monitoring treatment using a panel or panels of small molecule metabolite biomarkers are disclosed. The biomarkers are sensitive and specific for the detection of HCC, and can also be used to classify HCV infections that are regarded as precursors of HCC. |